Allergan and Sosei have voluntarily paused development of HTL0018318 after tests in nonhuman primates uncovered unexpected toxicology findings. Phase 1 and 2 clinical trials of the muscarinic M1 receptor agonist are on hold while the partners investigate the toxicology results.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,